BioSpace News Archive

Arrowhead Pharmaceuticals Inc. announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

Soliton, Inc. has been invited to present at Oppenheimer’s 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at The Westin New York Grand Central in New York City.

Halo Labs Inc. is pleased to provide a progress update on its Nevada business.

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis.

The latest addition to Vasayo’s Board of Directors has vast expertise in market expansion and industry legal affairs.

Cost savings from reduced need for clinical visits and prescription drugs due to OTCs saves U.S. health system $146 billion annually

Cellesce and Hubrecht Organoid Technology (HUB) have today announced a licence agreement for the expansion of organoids using Cellesce’s own bioprocessing technology and HUB Organoid Technology for the scale up of breast organoids.

Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. (“Imara”), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease (“SCD”) and other hemoglobinopathies.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Corcept Therapeutics Incorporated between August 2, 2017 and February 5, 2019, both dates inclusive.

Aptar Pharma, a leading drug delivery systems provider, is pleased to announce that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression.